View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 7, 2022

CCTG receives $30m Canadian Cancer Society grant to run clinical trials

The award will aid CCTG in supporting its key goals as well as the development and execution of trials.

National research network Canadian Cancer Trials Group (CCTG) has obtained a grant of $30m from the Canadian Cancer Society (CCS) to guarantee continued access to impactful clinical trials.

The latest five-year funding is a renewal of CCS’ support of CCTG. 

The process of renewal comprises a thorough review including a complete grant submission and site visit with external reviewers who examine all the elements of the CCTG’s work and its effect on clinical trials research. 

CCS Mission, Research & Advocacy executive vice-president Dr Stuart Edmonds said: “CCS is proud to continue to provide core funding for CCTG, and we’re incredibly grateful to our donors who make this support possible. 

“With an international reputation for running Canada’s most impactful cancer clinical trials, CCTG’s work benefits not just people with cancer in Canada but around the world.”

The latest funds will aid CCTG in supporting its key goals as well as the development and execution of trials. 

Boosting cancer outcomes in collaboration with patients is a key part of the research initiatives of CCTG. 

The group’s Patient Representative Committee guarantees that the requirements and priorities of the patients are taken into account in all trial designs and works.

CCTG director Dr Janet Dancey said: “The successful CCS grant renewal is a recognition of the exceptional calibre of our national scientific leaders, international research activities and the impact our trials have on new treatments for people with cancer. 

“The funding will ensure that Canadian led trials find answers to what is most important to Canadian patients and clinicians.”

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy